Premium
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Author(s) -
Sesques Pierre,
Ferrant Emmanuelle,
Safar Violaine,
Wallet Florent,
Tordo Jérémie,
Dhomps Anthony,
Karlin Lionel,
Brisou Gabriel,
Vercasson Marlène,
HospitalGustem Carole,
Schwiertz Vérane,
Ranchon Florence,
Rioufol Catherine,
Choquet Marion,
Sujobert Pierre,
Ghergus Dana,
Bouafia Fadhela,
Golfier Camille,
Lequeu Helène,
Lazareth Anne,
Novelli Silvana,
Devic Perrine,
Traverse Glehen Alexandra,
Viel Sébastien,
Venet Fabienne,
Mialou Valérie,
Hequet Olivier,
Chauchet Adrien,
Arkam Yazid,
NicolasVirelizier Emmanuelle,
Peyrade Frederic,
Cavalieri Doriane,
Ader Florence,
Ghesquières Hervé,
Salles Gilles,
Bachy Emmanuel
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25951
Subject(s) - medicine , cytokine release syndrome , refractory (planetary science) , gastroenterology , lymphoma , single center , chimeric antigen receptor , surgery , immunotherapy , cancer , physics , astrobiology
Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of use, efficacy and safety for axi‐cel and tisa‐cel. Data from 70 patients who underwent apheresis for commercial CAR T cells between January 2018 and November 2019 in our institution were retrospectively collected. Sixty‐one patients were infused. The median age at infusion was 59 years old (range 27‐75 years). The median number of prior therapies was 3 (range, 2‐6). The overall response rates (ORRs) at 1 month and 3 months were 63% and 45%, respectively, with 48% and 39% achieving a complete response (CR), respectively. After a median follow‐up after infusion of 5.7 months, the median progression‐free survival (PFS) was 3.0 months (95% CI, 2.8‐8.8 months), and the median overall survival (OS) was 11.8 months (95% CI, 6.0‐12.6 months). In multivariate analysis, factors associated with poor PFS were the number of previous lines of treatment before CAR T cells (≥4) ( P = .010) and a C reactive protein (CRP) value >30 mg/L at the time of lymphodepletion ( P < .001). Likewise, the only factor associated with a shorter OS was CRP >30 mg/L ( P = .009). Cytokine release syndrome (CRS) of any grade occurred in 85% of patients, including 8% of patients with CRS of grade 3 or higher. Immune cell‐associated neurotoxicity syndrome (ICANS) of any grade occurred in 28% of patients, including 10% of patients with ICANS of grade 3 or higher. Regarding efficacy and safety, no significant difference was found between axi‐cel and tisa‐cel. This analysis describes one of the largest real‐life cohorts of patients treated with axi‐cel and tisa‐cel for R/R aggressive B cell lymphoma in Europe.